PMC8733571_01
Procedure of CD19 CAR-T cell manufacture and the clinical application scheme. CAR-T, chimeric antigen receptor T cell; CTX, cyclophosphamide; Gemox-R, Gemcitabine, Oxaliplatin, and Rituximab; HLH, hemophagocytic lymphohistiocytosis; VP16, etoposide.
fonc-11-798352-g001.jpg
PMC8733571_01_fonc-11-798352-g001.jpg
f1
The infusion process was smooth, and the patient had no obvious adverse reactions ( Figure 1 ). After the platelet level of the patient returned to normal levels, sirolimus dose was gradually decreased by 0.5 mg every 3 days and finally stopped ( Figure 2 ;  Supplementary Figure 1 ;  Supplementary Data ).
Hematological adverse events and recovery after anti-CD19 CAR-T-cell therapy and sirolimus for r/r DLBCL.
fonc-11-798352-g002.jpg
PMC8733571_01_fonc-11-798352-g002.jpg
f2
After the platelet level of the patient returned to normal levels, sirolimus dose was gradually decreased by 0.5 mg every 3 days and finally stopped ( Figure 2 ;  Supplementary Figure 1 ;  Supplementary Data ).
Remission status r/r DLBCL after anti-CD19 CAR-T-cell therapy and sirolimus. (A) Full-body 18FDG-PET scan pre- anti-CD19 CAR-T-cell therapy. (B) full-body 18FDG-PET scan post- anti-CD19 CAR-T-cell therapy.
fonc-11-798352-g003.jpg
PMC8733571_01_fonc-11-798352-g003.jpg
f3
The Deauville score was 5 points ( Figure 3A ). The Deauville score was 1 point ( Figure 3B ).